Literature DB >> 27366215

Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease.

David Briskey1, Mandy Heritage2, Lesley-Anne Jaskowski2, Jonathan Peake3, Glenda Gobe4, V Nathan Subramaniam5, Darrell Crawford2, Catherine Campbell6, Luis Vitetta7.   

Abstract

BACKGROUND: We have investigated the effects of a multispecies probiotic preparation containing a combination of probiotic bacterial genera that included Bifidobacteria, Lactobacilli and a Streptococcus in a mouse model of high-fat diet or obesity-induced liver steatosis.
METHODS: Three groups of C57B1/6J mice were fed either a standard chow or a high-fat diet for 20 weeks, while a third group was fed a high-fat diet for 10 weeks and then concomitantly administered probiotics for a further 10 weeks. Serum, liver and large bowel samples were collected for analysis.
RESULTS: The expression of the tight-junction proteins ZO-1 and ZO-2 was reduced (p < 0.05) in high-fat diet-fed mice compared to chow-fed mice. Probiotic supplementation helped to maintain tight ZO-1 and ZO-2 expression compared with the high-fat diet group (p < 0.05), but did not restore ZO-1 or ZO-2 expression compared with chow-fed mice. Mice fed a high-fat diet ± probiotics had significant steatosis development compared with chow-fed mice (p < 0.05); steatosis was less severe in the probiotics group compared with the high-fat diet group. Hepatic triglyceride concentration was higher in mice fed a high-fat diet ± probiotics compared with the chow group (p < 0.05), and was lower in the probiotics group compared with the high-fat diet group (p < 0.05). Compared with chow-fed mice, serum glucose, cholesterol concentration and the activity of alanine transaminase were higher (p < 0.05), whereas serum triglyceride concentration was lower (p < 0.05) in mice fed a high-fat diet ± probiotics.
CONCLUSIONS: Supplementation with a multispecies probiotic formulation helped to maintain tight-junction proteins ZO-1 and ZO-2, and reduced hepatic triglyceride concentration compared with a high-fat diet alone.

Entities:  

Keywords:  dysbiosis; nonalcoholic fatty liver disease; probiotics; steatosis; tight-junction proteins

Year:  2016        PMID: 27366215      PMCID: PMC4913342          DOI: 10.1177/1756283X16645055

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  32 in total

1.  Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.

Authors:  R Aller; D A De Luis; O Izaola; R Conde; M Gonzalez Sagrado; D Primo; B De La Fuente; J Gonzalez
Journal:  Eur Rev Med Pharmacol Sci       Date:  2011-09       Impact factor: 3.507

Review 2.  Intestinal epithelial cells: regulators of barrier function and immune homeostasis.

Authors:  Lance W Peterson; David Artis
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

3.  Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells.

Authors:  Nadège Parassol; Miguel Freitas; Karine Thoreux; Guillaume Dalmasso; Raphaelle Bourdet-Sicard; Patrick Rampal
Journal:  Res Microbiol       Date:  2004-12-15       Impact factor: 3.992

4.  Dynamics of gut colonization and source of intestinal flora in healthy newborn infants.

Authors:  Terhi Tapiainen; Samuli Ylitalo; Erkki Eerola; Matti Uhari
Journal:  APMIS       Date:  2006-11       Impact factor: 3.205

Review 5.  Obesity-associated liver disease.

Authors:  Giulio Marchesini; Simona Moscatiello; Silvia Di Domizio; Gabriele Forlani
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

6.  Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Won; Angel Mei-Ling Chim; Winnie Chiu-Wing Chu; David Ka-Wai Yeung; Kevin Chi-To Li; Henry Lik-Yuen Chan
Journal:  Ann Hepatol       Date:  2013 Mar-Apr       Impact factor: 2.400

7.  Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model.

Authors:  Laetitia Rodes; Afshan Khan; Arghya Paul; Michael Coussa-Charley; Daniel Marinescu; Catherine Tomaro-Duchesneau; Wei Shao; Imen Kahouli; Satya Prakash
Journal:  J Microbiol Biotechnol       Date:  2013-04       Impact factor: 2.351

8.  Prevalence of NAFLD in Healthy and Young Male Individuals.

Authors:  Asif Niaz; Zafar Ali; Shaista Nayyar; Naureen Fatima
Journal:  ISRN Gastroenterol       Date:  2011-06-08

9.  Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.

Authors:  Weiwei Jiang; Na Wu; Xuemei Wang; Yujing Chi; Yuanyuan Zhang; Xinyun Qiu; Ying Hu; Jing Li; Yulan Liu
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379

10.  Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.

Authors:  Helen Waller-Evans; Christophe Hue; Jane Fearnside; Alice R Rothwell; Helen E Lockstone; Sophie Caldérari; Steven P Wilder; Jean-Baptiste Cazier; James Scott; Dominique Gauguier
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more
  14 in total

Review 1.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

Review 2.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

3.  Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Petro Bodnar; Tetyana Beregova
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

Review 4.  Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease.

Authors:  Emma T Saltzman; Talia Palacios; Michael Thomsen; Luis Vitetta
Journal:  Front Microbiol       Date:  2018-01-30       Impact factor: 5.640

5.  Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury.

Authors:  Lei Yu; Xue-Ke Zhao; Ming-Liang Cheng; Guo-Zhen Yang; Bi Wang; Hua-Juan Liu; Ya-Xin Hu; Li-Li Zhu; Shuai Zhang; Zi-Wen Xiao; Yong-Mei Liu; Bao-Fang Zhang; Mao Mu
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

Review 6.  Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.

Authors:  Jiezhong Chen; Luis Vitetta
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 7.  Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Shuhei Nishiguchi; Hiroko Iijima
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

Review 8.  Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.

Authors:  Ashiq Khan; Zitong Ding; Muhammad Ishaq; Ali Sher Bacha; Israr Khan; Anum Hanif; Wenyuan Li; Xusheng Guo
Journal:  Int J Biol Sci       Date:  2021-02-08       Impact factor: 6.580

9.  Supplemental Bacillus subtilis PB6 Improves Growth Performance and Gut Health in Broilers Challenged with Clostridium perfringens.

Authors:  Yan Liu; Song Zhang; Zheng Luo; Dan Liu
Journal:  J Immunol Res       Date:  2021-10-27       Impact factor: 4.818

Review 10.  Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages.

Authors:  Luis Vitetta; Gemma Vitetta; Sean Hall
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.